DelveInsight’s, “Charcot Marie Tooth Disease Pipeline Insight, 2026” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Charcot Marie Tooth Disease pipeline landscape. It covers the Charcot Marie Tooth pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Charcot Marie Tooth therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Charcot Marie Tooth Pipeline? @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-pipeline-insight

Key Takeaways from the Charcot Marie Tooth Pipeline Report

• On May 29, 2026, Novartis Pharmaceuticals conducted a study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants. The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS). The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
• On May 26, 2026- ENCell initiated a phase 1b study was designed using the traditional 3+3 dose escalation method to confirm the maximum tolerated dose (MTD) and determine the recommended phase 2 dose (RP2D). This clinical trial consists of two stages (Phase 1b and Phase 2a). Phase 1b is designed with a 3+3 dose escalation design to evaluate the safety, including tolerability, of EN001 and explore efficacy. Phase 2a will evaluate the efficacy and safety of EN001 in comparison with placebo.
• DelveInsight’s Charcot Marie Tooth Pipeline report depicts a robust space with 13+ active players working to develop 15+ pipeline therapies for Charcot Marie Tooth treatment.
• The leading Charcot Marie Tooth Companies include Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals, and others.
• Promising Charcot Marie Tooth Therapies such as PXT3003, NMD670, MD1003, Engensis (VM202), Remibrutinib, Teriflunomide, Cladribine (MAVENCLAD®) and others.

Want to know which companies are leading innovation in Charcot Marie Tooth? Dive into the full pipeline insights @ Charcot Marie Tooth Clinical Trials Assessment

Charcot Marie Tooth Overview

Charcot-Marie-Tooth disease (CMT) is a group of inherited neurological disorders that affect the peripheral nerves, which are responsible for movement and sensation in the limbs. Named after the three physicians who first described it in 1886, CMT is also known as hereditary motor and sensory neuropathy (HMSN). It is one of the most common inherited neurological disorders, affecting about 1 in 2,500 people. CMT is characterized by progressive muscle weakness and atrophy, primarily in the legs and feet, and, in later stages, in the hands and arms.

Charcot Marie Tooth Disease Emerging Drugs Profile

• Ignaseclant: NMD PHARMA

Ignaseclant (NMD670) is an investigational, first-in-class oral small molecule that selectively inhibits the skeletal muscle chloride channel ClC-1 chloride channel. By regulating this channel, it increases muscle excitability and enhances neuromuscular signal transmission. The therapy is being developed to improve muscle function and alleviate fatigue in patients with Charcot-Marie-Tooth disease. It is currently undergoing Phase II clinical evaluation for the treatment of Charcot-Marie-Tooth disease.

• EN001: ENCell

EN001 is an investigational therapeutic being developed for the treatment of Charcot-Marie-Tooth disease, a genetic disorder characterized by progressive muscle weakness and sensory loss. The drug is designed to enhance neuromuscular function by targeting pathways involved in muscle strength and nerve signaling. By improving muscle performance and reducing fatigue, EN001 aims to address key functional impairments associated with the disease. The drug has recently completed Phase I of clinical trials.

If you’re tracking ongoing Charcot Marie Tooth Clinical trials, this press release is a must-read @ Charcot Marie Tooth Treatment Drugs

Charcot Marie Tooth Companies

Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine Therapeutics, Novartis Pharmaceuticals, and others.

The Charcot Marie Tooth Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Charcot Marie Tooth with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Charcot Marie Tooth Treatment.
• Charcot Marie Tooth Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Charcot Marie Tooth Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Charcot Marie Tooth market.

Charcot Marie Tooth Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Charcot Marie Tooth Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Charcot Marie Tooth Pipeline Report covers it all @ Charcot Marie Tooth Market Drivers and Barriers, and Future Perspectives

Scope of the Charcot Marie Tooth Pipeline Report

• Coverage- Global
• Charcot Marie Tooth Companies- Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals, and others.
• Charcot Marie Tooth Therapies- PXT3003, NMD670, MD1003, Engensis (VM202), Remibrutinib, Teriflunomide, Cladribine (MAVENCLAD®) and others.
• Charcot Marie Tooth Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Charcot Marie Tooth Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Charcot Marie Tooth Treatment landscape in this detailed analysis @ Charcot Marie Tooth Emerging Drugs and Major Players

Table of Content

1. Introduction
2. Executive Summary
3. Charcot Marie Tooth Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Charcot Marie Tooth Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. PXT3003: Pharnext SA
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IFB-088: InFlectis BioScience
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Charcot Marie Tooth Disease Key Companies
21. Charcot Marie Tooth Disease Key Products
22. Charcot Marie Tooth Disease- Unmet Needs
23. Charcot Marie Tooth Disease- Market Drivers and Barriers
24. Charcot Marie Tooth Disease- Future Perspectives and Conclusion
25. Charcot Marie Tooth Disease Analyst Views
26. Charcot Marie Tooth Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-pipeline-insight